Last reviewed · How we verify
Artiss
Artiss, marketed by Zuyderland Medisch Centrum, is a drug with a key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, leveraging its established position. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Artiss |
|---|---|
| Also known as | Artiss glue |
| Sponsor | Zuyderland Medisch Centrum |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- ARTISS a Single-centre Randomised Control Study (PHASE4)
- A Study Evaluating the Efficacy and Safety of ARTISS Human Fibrin Sealant as Used in External Rhinoplasty (PHASE2)
- Seroma Reduction After Mastectomy (PHASE4)
- Efficacy and Safety of ARTISS for Flap Adherence in Abdominoplasty (PHASE2)
- Safety and Efficacy Study of FS 4 IU VH S/D (Fibrin Sealant With 4IU/mL Thrombin, Vapor Heated, Solvent/Detergent Treated) to Adhere Split Thickness Skin Grafts and Improve Wound Healing in Burn Patients (PHASE3)
- Efficacy and Safety of FS VH S/D 4 S-apr for Flap Adherence in Rhytidectomy (PHASE3)
- Efficacy and Safety of Fibrin Sealant (FS) VH S/D-APR for Hemostasis and Wound Healing in Endoscopic Browlift
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Artiss CI brief — competitive landscape report
- Artiss updates RSS · CI watch RSS
- Zuyderland Medisch Centrum portfolio CI